These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25534682)

  • 1. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
    Zhang J; Thapar M; Farrell C; Wire MB
    Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
    Farrell C; Hayes SC; Wire M; Zhang J
    Br J Clin Pharmacol; 2014 Mar; 77(3):532-44. PubMed ID: 24117976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
    Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
    Saleh MI; Melhim SB; Al-Ramadhani HM; Alzubiedi S
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):31-42. PubMed ID: 29948848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
    Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
    J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
    Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
    Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
    Wire MB; Li X; Zhang J; Sallas W; Aslanis V; Ouatas T
    Clin Pharmacol Ther; 2018 Dec; 104(6):1199-1207. PubMed ID: 29536526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
    Saleh MI; Obeidat AR; Anter HA; Khanfar AA
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1030-5. PubMed ID: 26173631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
    J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
    Tillmann HL; Patel K; McHutchison JG
    Curr Gastroenterol Rep; 2009 Feb; 11(1):5-14. PubMed ID: 19166653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
    Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
    J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection.
    Alzubiedi S; Saleh MI
    Am J Ther; 2017; 24(6):e670-e675. PubMed ID: 26460746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.
    Hayes S; Ouellet D; Zhang J; Wire MB; Gibiansky E
    J Clin Pharmacol; 2011 Oct; 51(10):1403-17. PubMed ID: 21148042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
    Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
    Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
    Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
    Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
    [No Abstract]   [Full Text] [Related]  

  • 20. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
    Grotzinger KM; Younossi ZM; Giannini EG; Chen PJ; Rendas-Baum R; Theodore D
    Health Qual Life Outcomes; 2016 Mar; 14():49. PubMed ID: 27004952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.